A Study of Intra-tumoral Administered MTX110 in Patients With Recurrent Glioblastoma
Stopped early · Phase 1
Conditions studied: Recurrent Glioblastoma
In brief
A study designed to assess the safety of MTX110 in patients suffering with recurrent glioblastoma. MTX110 will be administered directly to the site of the tumour via a catheter which is inserted during a surgical procedure at the beginning of the study.
Key facts
- Study ID
- NCT05324501
- Run by
- Biodexa Pharmaceuticals
- People needed
- 4
- Starts
- 2022-10-19
- Expected to finish
- 2024-09-10
- Last updated by the study team
- 2025-02-10
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Recurrent glioblastoma.
- Patients must be healthy enough to tolerate surgery and general anesthesia.
- Estimated life expectancy of greater than 3 months.
You may not qualify if…
- Patients scheduled to undergo or are undergoing re-irradiation for the recurrent tumour.
- Patients with a history of glioblastoma treatment with carmustine or Gliadel® wafers.
- Patients who cannot undergo MRI.
- Patients may not have received chemotherapy or bevacizumab ≤ 4 weeks, or metronomic dosed chemotherapy such as daily etoposide or cyclophosphamide (1 week) prior to starting the study drug.
- Patients may not have received treatment with tumor treating fields ≤ 1 week prior to starting the study drug.
- Patients may not be less than 12 weeks from completion of radiation therapy for the primary tumor.
- Patients with neoplastic lesions in the brainstem, cerebellum, or spinal cord; radiological evidence of active; multifocal disease; extensive subependymal disease (tumor touching subependymal space is allowed); tumor crossing the midline or leptomeningeal disease.
- Posterior fossa location of the tumor, regardless of its morphology.
- Prior, unrelated malignancy requiring current active treatment with the exception of cervical carcinoma in situ and adequately treated basal cell or squamous cell carcinoma of the skin (treatment with tamoxifen or aromatase inhibitors or other hormonal therapy that may be indicated in prevention of prior cancer disease recurrence, are not considered current active treatment).
Where it is running
- Baptist MD Anderson — Jacksonville, Florida, United States
- Duke University Hospital — Durham, North Carolina, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.